Advanced Search
MyIDEAS: Login to save this article or follow this journal

The intensity of competition after patent expiry in pharmaceuticals. A cross-country analysis

Contents:

Author Info

  • Laura Magazzini
  • Luigi Orsenigo
  • Fabio Pammolli

Abstract

[fre] Les relations entre les évolutions des prix, l'expiration des brevets et la concurrence varient considérablement, selon les pays. Une distinction nette apparaît. Dans les pays (États-Unis en particulier), dans lesquels domine la concurrence de marché, une distinction claire s'impose entre les firmes innovatrices et les firmes qui imitent après l'expiration des brevets. Les produits originaux bénéficient de primes importantes jusqu'à l'expiration des brevets, qui enclenche une concurrence féroce. Dans les pays à prix administrés (en particulier la France et l'Italie), le système encourage des stratégies de prolifération des marques et de différenciation horizontale, par voie d'imitation bien avant l'expiration des brevets. Ces systèmes à prix administrés ont tendance à étouffer la concurrence par les prix, à protéger les entreprises moins efficientes et à encourager des stratégies d'innovation incrémentales, par imitation. [eng] This paper shows that the relationships between the dynamics of drug priees, patent expiry, and competition by multisource drugs vary significantly across countries. A clear distinction seems to emerge. On the one side, systems that rely on market based competition (particularly the US) promote a clear distinction between firms that act as innovators and firms that act as imitators after patent expiry. Original products enjoy premium prices under patent protection, and face fierce price competition after patent expiry. On the contrary, systems that rely on administered prices (particularly France and Italy) nurture strategies of pre-emptive brand proliferation and horizontal differentiation by imitative brand name products, well before patent expiry. Our work confirms that that systems that rely on administered prices have tended to stifle price competition, to protect less efficient companies, and to encourage strategies of incremental innovation and imitation.

Download Info

If you experience problems downloading a file, check if you have the proper application to view it first. In case of further problems read the IDEAS help page. Note that these files are not on the IDEAS site. Please be patient as the files may be large.
File URL: http://dx.doi.org/10.3406/rei.2002.1829
Download Restriction: no

File URL: http://www.persee.fr/articleAsPDF/rei_0154-3229_2002_num_99_1_1829/rei_0154-3229_2002_num_99_1_1829.pdf?mode=light
Download Restriction: no

Bibliographic Info

Article provided by Programme National Persée in its journal Revue d'économie industrielle.

Volume (Year): 99 (2002)
Issue (Month): 1 ()
Pages: 107-131

as in new window
Handle: RePEc:prs:recind:rei_0154-3229_2002_num_99_1_1829

Note: DOI:10.3406/rei.2002.1829
Contact details of provider:
Web page: http://www.persee.fr/web/revues/home/prescript/revue/rei

Related research

Keywords:

References

No references listed on IDEAS
You can help add them by filling out this form.

Citations

Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
as in new window

Cited by:
  1. Gianluca Baio & Laura Magazzini & Antonio Nicita & Fabio Pammolli & Massimo Riccaboni, 2003. "Il Decreto DL 15/04/2002, n. 63 sul Contenimento della Spesa Farmaceutica," Working Papers 0-2003, Competitività Regole Mecati (CERM).
  2. Herrmann, Andrea M., 2008. "On the discrepancies between macro and micro level identification of competitive strategies," MPIfG Discussion Paper 08/6, Max Planck Institute for the Study of Societies.
  3. Laura Magazzini & Fabio Pammolli & Massimo Riccaboni, 2004. "Dynamic competition in pharmaceuticals," The European Journal of Health Economics, Springer, vol. 5(2), pages 175-182, May.
  4. Suhrcke, Marc & Pelgrin, Florian & Oliveira Martins, Joaquim & Dormont, Brigitte, 2007. "Health expenditures, longevity and growth," Economics Papers from University Paris Dauphine 123456789/3882, Paris Dauphine University.
  5. Herrmann, Andrea M., 2008. "Choosing and successfully sustaining competitive strategies in the European pharmaceutical industry," MPIfG Discussion Paper 08/9, Max Planck Institute for the Study of Societies.
  6. Patricia M. Danzon & Michael F. Furukawa, 2011. "Cross-National Evidence on Generic Pharmaceuticals: Pharmacy vs. Physician-Driven Markets," NBER Working Papers 17226, National Bureau of Economic Research, Inc.
  7. Jean-Paul Moatti & Bruno Ventelou, 2009. "Économie de la santé dans les pays en développement des paradigmes en mutation," Revue économique, Presses de Sciences-Po, vol. 60(2), pages 241-256.
  8. Herrmann, Andrea M. & Peine, Alexander, 2011. "When 'national innovation system' meet 'varieties of capitalism' arguments on labour qualifications: On the skill types and scientific knowledge needed for radical and incremental product innovations," Research Policy, Elsevier, vol. 40(5), pages 687-701, June.
  9. Leopold, Christine & Mantel-Teeuwisse, Aukje Katja & Vogler, Sabine & de Joncheere, Kees & Laing, Richard Ogilvie & Leufkens, Hubert G.M., 2013. "Is Europe still heading to a common price level for on-patent medicines? An exploratory study among 15 Western European countries," Health Policy, Elsevier, vol. 112(3), pages 209-216.
  10. Magazzini, Laura & Pammolli, Fabio & Riccaboni, Massimo, 2004. "Dynamic Competition in Pharmaceuticals: Patent Expiry, Generic Penetration, and Industry Structure," MPRA Paper 15968, University Library of Munich, Germany.

Lists

This item is not listed on Wikipedia, on a reading list or among the top items on IDEAS.

Statistics

Access and download statistics

Corrections

When requesting a correction, please mention this item's handle: RePEc:prs:recind:rei_0154-3229_2002_num_99_1_1829. See general information about how to correct material in RePEc.

For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Equipe PERSEE).

If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

If references are entirely missing, you can add them using this form.

If the full references list an item that is present in RePEc, but the system did not link to it, you can help with this form.

If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your profile, as there may be some citations waiting for confirmation.

Please note that corrections may take a couple of weeks to filter through the various RePEc services.